Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its price objective raised by HC Wainwright from $535.00 to $550.00 in a research note released on Friday,Benzinga reports. HC Wainwright ...

FDA approval of ALYFTREK and TRIKAFTA expands CF treatment options ... Get Wall Street's Hottest Chart Every Morning RBC Capital Markets says Vertex management is optimistic about the recently ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

TRIKAFTA: Also on December 20, 2024, Vertex received FDA approval for the expanded use of TRIKAFTA in patients with 94 additional non-F508del CFTR mutations. With this approval, approximately 300 ...

AbbVie, Vertex Pharmaceuticals, Eli Lilly and Company, Thermo Fisher Scientific, and Colgate-Palmolive are the five Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool.